An onslaught of new setbacks due to FSHD disease progression has left columnist Robin Stemple understandably anxious about ...

Adeno-associated virus (AAV)–mediated gene therapy was one of the focal points of this year's Muscular Dystrophy Association conference. Here, Barry Byrne, MD, PhD, University of Florida, speaks to ...

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule.

Distinguished new members of the FSHD Society's Board of Directors bring expertise to help accelerate treatments and expand advocacy for the FSH muscular dystrophy community. Mel Hayes, a seasoned ...

candidate for myotonic dystrophy type 1 (DM1), and del-brax for facioscapulohumeral muscular dystrophy (FSHD). All three candidates are based on the same TfR1-targeting antibody component.

BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (NASDAQ:DYN), focused on developing therapies for ...

MOVE Peds will enroll pediatric FSHD patients across eight clinical sites, capturing both early-onset and later-onset pediatric forms of the disease. Using MRI and functional testing optimized for ...

the first large-scale clinical study focused on pediatric facioscapulohumeral muscular dystrophy (FSHD; NCT06847282). The study, led by top neuromuscular experts and funded by the NIH, aims to ...